Program Schedule

1178
Comparison of the Accelerated and Standard Vaccination Schedules Against Hepatitis B in Healthy Adults

Session: Poster Abstract Session: Viral Infections: Treatment and Prevention
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background:

In our country, premarital screening for hepatitis B (HB) virus infection is systematic. Immunization against HB virus is indicated for partner at risk. The aim of this study was to compare the immune response and the compliance of an accelerated (A; days 0, 7, 21) and standard (B; days 0, 30, 180) HB vaccination schedules.

Methods:

A prospective study was performed between January 2007 and January 2013. Recombinant HB vaccine was given as 20 micrograms intramuscularly. The anti-HBs antibody was determined 30 days after completion of the third vaccine injection in both groups. A seroprotective titer was defined as 10 IU/L. The non-responders received new monthly doses of vaccine (maximum 3 doses). The anti-HBs antibody was determined 30 days after each injection.

Results:

Our study included 466 (117 men, 349 women) healthy adults. The mean age was 28 ± 6 years. Three hundred ninety nine (84.3 %) assigned to schedule A and 73 (15.7%) to schedule B according to the delay between the first consultation and the marriage. One month after the third dose, 56% (schedule A) and 59% (schedule B) of the subjects were seroprotected. The compliance with four doses was significantly better in schedule A rather than schedule B (p = 0.004). Anti-HBs geometric mean titers were higher in group B than in group A (p = 0.009). After four doses of vaccine, the seroprotective rate was 82% and 91.2 % for schedule A and B respectively. At the end of the protocol, the seroprotective rate was 99.4% and 100% for schedule A and B respectively (p= 0.4).

Conclusion:

A 3-week HB vaccination schedule confer good and early protective immunity. Therefore it seems to be a good preference for last minute immunization in premarital examination.

Makram Koubaa, MD1, Chakib Marrakchi, MD1, Boussaima Hammami, MD1, Kaoula Rekik, MD1, Najoua Kteta, MD2, Imed Maaloul, MD1, Lamia Berrajah, MD3 and Mounir Ben Jemaa, MD1, (1)Department of Infectious Diseases, Hedi Chaker University Hospital, Sfax, Tunisia, (2)Department of basic Health Care, Sfax, Tunisia, (3)Department of Microbiology, Habib Bourguiba University Hospital, Sfax, Tunisia

Disclosures:

M. Koubaa, None

C. Marrakchi, None

B. Hammami, None

K. Rekik, None

N. Kteta, None

I. Maaloul, None

L. Berrajah, None

M. Ben Jemaa, None

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek